Quarterly Results Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Dec'23
Net Sales
204.83
166.89
148.26
143.12
132.12
108.01
104.03
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
204.83
166.89
148.26
143.12
132.12
108.01
104.03
Raw Material Cost
31.70
31.82
23.32
22.88
22.36
19.16
20.74
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
6.67
7.21
7.10
6.45
8.33
7.01
6.24
Selling and Distribution Expenses
138.44
104.48
93.82
78.47
70.56
70.37
69.44
Other Expenses
7.96
8.71
10.05
7.75
8.08
6.97
14.62
Total Expenditure (Excl Depreciation)
256.44
230.56
224.71
185.35
182.09
166.24
242.65
Operating Profit (PBDIT) excl Other Income
-51.6
-63.7
-76.5
-42.199999999999996
-50
-58.2
-138.6
Other Income
14.54
40.56
41.09
15.28
23.30
17.14
62.12
Operating Profit (PBDIT)
-26.03
-8.71
-18.68
-10.27
-12.69
-27.11
-62.08
Interest
6.67
7.21
7.10
6.45
8.33
7.01
6.24
Exceptional Items
0.00
0.00
0.02
0.29
1.13
2.48
0.93
Gross Profit (PBDT)
173.13
135.07
124.94
120.24
109.77
88.85
83.28
Depreciation
14.40
14.40
16.68
16.68
13.98
13.98
14.43
Profit Before Tax
-47.10
-30.32
-42.45
-33.11
-33.87
-45.62
-81.82
Tax
-0.84
-1.00
-1.79
-0.99
-0.97
-0.99
-0.98
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
-44.54
-28.26
-39.93
-31.37
-27.04
-39.50
-76.49
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
-44.54
-28.26
-39.93
-31.37
-27.04
-39.50
-76.49
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-1.72
-1.05
-0.72
-0.75
-5.86
-5.13
-4.35
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
-46.26
-29.31
-40.65
-32.12
-32.90
-44.63
-80.84
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
1,176.62
1,226.01
1,253.86
1,303.39
1,567.04
1,593.69
1,632.85
Earnings per share (EPS)
-0.17
-0.11
-0.15
-0.12
-0.1
-0.15
-0.29
Diluted Earnings per share
-0.17
-0.11
-0.15
-0.12
-0.1
-0.15
-0.29
Operating Profit Margin (Excl OI)
-26.84%
-38.15%
-51.57%
-29.51%
-37.82%
-53.91%
-133.26%
Gross Profit Margin
-15.96%
-9.54%
-17.38%
-11.48%
-15.05%
-29.3%
-64.78%
PAT Margin
-21.75%
-16.93%
-26.93%
-21.92%
-20.46%
-36.57%
-73.53%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Jun 2025 is 55.03% vs 18.26% in Jun 2024
Consolidate Net Profit
YoY Growth in quarter ended Jun 2025 is -40.73% vs 45.98% in Jun 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Jun 2025 is -12.78% vs 38.67% in Jun 2024
Interest
YoY Growth in quarter ended Jun 2025 is -19.28% vs 56.60% in Jun 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Jun 2025 has improved from Jun 2024
Compare Quarterly Results Of Suzhou Zelgen Biopharmaceuticals Co., Ltd. With
Figures in Million
Consolidate Quarterly Results
Change(CNY)
Change(%)
Net Sales
204.83
0
204.83
Other Operating Income
0.00
0.00
0.00
Total Operating income
204.83
0
204.83
Raw Material Cost
31.70
0
31.70
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
6.67
0
6.67
Selling and Distribution Expenses
138.44
0
138.44
Other Expenses
7.96
0.00
7.96
Total Expenditure (Excl Depreciation)
256.44
0
256.44
Operating Profit (PBDIT) excl Other Income
-51.61
0.00
-51.61
Other Income
14.54
0
14.54
Operating Profit (PBDIT)
-26.03
0
-26.03
Interest
6.67
0
6.67
Exceptional Items
0.00
0
0.00
Gross Profit (PBDT)
173.13
0
173.13
Depreciation
14.40
0
14.40
Profit Before Tax
-47.10
0
-47.10
Tax
-0.84
0
-0.84
Provisions and contingencies
0
0
0.00
Profit After Tax
-44.54
0
-44.54
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
-44.54
0
-44.54
Share in Profit of Associates
0
0
0.00
Minority Interest
-1.72
0
-1.72
Other related items
0.00
0.00
0.00
Consolidated Net Profit
-46.26
0
-46.26
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
1,176.62
0
1,176.62
Earnings per share (EPS)
-0.17
0
-0.17
Diluted Earnings per share
-0.17
0
-0.17
Operating Profit Margin (Excl OI)
-26.84%
0%
0.00
-26.84%
Gross Profit Margin
-15.96%
0%
0.00
-15.96%
PAT Margin
-21.75%
0%
0.00
-21.75%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 20.48 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is 22.71% vs 12.54% in Mar 2025
YoY Growth in quarter ended Jun 2025 is 55.03% vs 18.26% in Jun 2024
Quarterly - Consolidate Net Profit
Consolidate Net Profit -4.63 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is -58.02% vs 28.01% in Mar 2025
YoY Growth in quarter ended Jun 2025 is -40.73% vs 45.98% in Jun 2024
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -4.06 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is 17.65% vs 17.56% in Mar 2025
YoY Growth in quarter ended Jun 2025 is -12.78% vs 38.67% in Jun 2024
Quarterly - Interest
Interest 0.67 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is -6.94% vs 1.41% in Mar 2025
YoY Growth in quarter ended Jun 2025 is -19.28% vs 56.60% in Jun 2024
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -26.84%
in Jun 2025Figures in %
QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025
YoY Growth in quarter ended Jun 2025 has improved from Jun 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
